Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P98194: Variant p.Leu341Pro

Calcium-transporting ATPase type 2C member 1
Gene: ATP2C1
Feedback?
Variant information Variant position: help 341 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 341 (L341P, p.Leu341Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HHD; decreases protein expression. Any additional useful information about the variant.


Sequence information Variant position: help 341 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 919 The length of the canonical sequence.
Location on the sequence: help GVMRMVKKRAIVKKLPIVET L GCCNVICSDKTGTLTKNEMT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GVMRMVKKRAIVKKLPIVETLGCCNVICSDKTGTLTKNEMT

Mouse                         GVMRMVKKRAIVKKLPIVETLGCCNVICSDKTGTLTKNEMT

Rat                           GVMRMVKKRAIVKKLPIVETLGCCNVICSDKTGTLTKNEMT

Bovine                        GVMRMVKKRAIVKKLPIVETLGCCNVICSDKTGTLTKNEMT
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 919 Calcium-transporting ATPase type 2C member 1
Topological domain 313 – 699 Cytoplasmic
Active site 350 – 350 4-aspartylphosphate intermediate
Mutagenesis 350 – 350 D -> A. Impairs pump activity.



Literature citations
Effect of Hailey-Hailey Disease mutations on the function of a new variant of human secretory pathway Ca2+/Mn2+-ATPase (hSPCA1).
Fairclough R.J.; Dode L.; Vanoevelen J.; Andersen J.P.; Missiaen L.; Raeymaekers L.; Wuytack F.; Hovnanian A.;
J. Biol. Chem. 278:24721-24730(2003)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 9); FUNCTION; SUBCELLULAR LOCATION; CATALYTIC ACTIVITY; CHARACTERIZATION OF VARIANTS HHD LEU-201; CYS-309; PRO-341; TYR-344; ARG-411; ILE-570; VAL-580; TYR-742 AND ARG-789; Hailey-Hailey disease: molecular and clinical characterization of novel mutations in the ATP2C1 gene.
Dobson-Stone C.; Fairclough R.; Dunne E.; Brown J.; Dissanayake M.; Munro C.S.; Strachan T.; Burge S.; Sudbrak R.; Monaco A.P.; Hovnanian A.;
J. Invest. Dermatol. 118:338-343(2002)
Cited for: VARIANTS HHD CYS-309; PRO-341; ARG-411; VAL-580; TYR-742 AND ARG-789;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.